Gonadotropin-Induced Spermatogenesis in CHH Patients with Cryptorchidism
Table 1
Comparison of baseline characteristics between the cryptorchidism and noncryptorchidism group.
Cryptorchidism (n = 40)
Noncryptorchidism (n = 183)
value
Proportion of Kallmann Syndrome
62.5% (25/40)
47.0% (86/183)
0.083
Age initiating treatment (y)
18.9 ± 4.6
20.4 ± 4.8
0.063
BMI (kg/m2)
21.2 ± 4.1
22.6 ± 3.7
0.027
Peak LH (IU/L)
0.8 (0.4, 3.3)
1.7 (0.7, 5.5)
0.812
Rate of CHH family history
7.5% (3/40)
8.2% (15/183)
0.591
Basal testicular volume (ml)
1.6 ± 1.1
2.2 ± 1.6
0.013
Testicular volume after treatment (ml)
6.2 ± 4.1
8.6 ± 4.6
0.003
Proportion of preandrogen therapy
72.5% (29/40)
55.7% (102/183)
0.054
Duration of androgen therapy (months)
17 (3, 45)
3 (3, 6)
0.061
Proportion of pre-HCG therapy
37.5% (15/40)
24.0% (44/183)
0.112
Duration of pre-HCG therapy (months)
6 (0, 23)
3 (3, 5)
0.070
Comorbidities
Obesity
10.0% (4/40)
10.4% (19/183)
0.878
Dwarfism
5.0% (2/40)
3.8% (7/183)
0.772
Mental retardation
2.5% (1/40)
2.2% (4/183)
0.583
Unilateral agenesis of the kidney
2.5% (1/40)
1.1% (2/183)
0.672
Cleft lip and palate
0.0% (0/40)
1.6% (3/183)
0.091
Statistical significance. was defined as significant difference. Data were expressed as median (25%, 75%). Peak LH: highest LH level after intramuscular injection of triptorelin 100 μg.
